I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

In a report released today, Allen Lutz from Bank of America Securities reiterated a Sell rating on Hims & Hers Health (HIMS – Research ...

that the duration of the semaglutide compounding opportunity may be shorter than some expected.” The firm, which thinks there is “less likelihood of material upside revisions to 2025 revenue ...

Many compounding pharmacies make unbranded versions of semaglutide, which has been on the U.S. market — and in short supply — ...

Novo specifically requested semaglutide be added to the FDA’s Demonstrable Difficulties for Compounding lists, citing complexities around formulations, delivery mechanisms, dosage forms ...